CpG-DNA, Mouse, BioGenomics(TM)

Bacterial DNA is known to induce acute inflammatory responses. Bacterial DNA acts as a pathogen-associated molecular pattern by virtue of a 20-fold greater frequency of unmethylated CG dinucleotides found in microbial DNA versus vertebrate DNA. Cellular activation by deoxy-cytidylate-phosphate-deoxy- guanylate (CpG)-DNA occurs via the Toll/IL-1R signal pathway. TLR9 appears to be a major component of the CpG-DNA receptor, acting by direct binding to CpG-DNA. The synthetic oligodeoxynucleotides (ODN) contain the proper CpG-DNA motif mimicing the immunostimulatory effects of bacterial DNA. The human optimal CpG motif GTCGTT differs from the optimal mouse CpG motif GACGTT. Non CpG-DNA has been shown to compete with CpG-DNA in in vitro stimulation experiments.\n\nSource:\nThis mouse CpG is a 20-mer ODN has the following sequence: 5'-tccatgacgttcctgatgct-3'. Regular letters represent phosphorothiorate linkage.\n\nApplications: \nSuitable for use for biological assays in vitro to activate murine cells. Other applications not tested.\n\nRecommended Dilutions:\nIn vitro Stimulation: 0.01-10uM\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with dH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C7905-85

Size

200nmol

Form

Supplied as a lyophilized powder. Reconstitute with dH2O.

Purity

Purified

References

1. Bauer, S et al; Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2003, 98: 9237. 2. Hemmi, H et al; A toll-like receptor recognizes bacterial DNA. Nature 2000, 408: 740.